Randomized control trial of fluorescence-guided surgical excision of nonmelanotic cutaneous malignancies

Journal of Otolaryngology

Volumn 36, Issue 3, 2007, Pages 148-155

  Brandt, Michael G ^a   Moore, Corey C ^a,c   Jordan, Kevin ^a,b  

^a WESTERN UNIVERSITY   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c ST JOSEPH S HEALTH CENTRE   (Canada)

Author keywords

Cutaneous malignancy; Fluorescence; Photodynamic photodelineation

Indexed keywords

AMINOLEVULINIC ACID; PROTOPORPHYRIN;

AGED; ARTICLE; CANCER CENTER; CANCER RECURRENCE; CANCER SURGERY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FLUORESCENCE; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOLOGICAL ANATOMY; PHOTODYNAMICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REOPERATION; SKIN CANCER; STATISTICAL SIGNIFICANCE; SURGEON; SURGICAL ANATOMY; SURGICAL APPROACH; SURGICAL TECHNIQUE; TERTIARY HEALTH CARE;

AGED; FEMALE; FLUORESCENCE; HUMANS; MALE; PHOTOSENSITIZING AGENTS; PROSPECTIVE STUDIES; PROTOPORPHYRINS; SKIN NEOPLASMS; SURGERY, COMPUTER-ASSISTED;

EID: 34748822245     PISSN: 03816605     EISSN: None     Source Type: Journal    
DOI: 10.2310/7070.2007.0020     Document Type: Article

References (13)

1. Canadian Cancer Society/National Cancer Institute of Canada. Canadian cancer statistics 2005. Toronto 2005.
2. Kennedy JC, Marcus SL, Pottier RH. Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): mechanisms and clinical results. J Clin Laser Med Surg 1996;14:289-304.
3. Moan J, Peng Q. An outline of the hundred-year history of PDT. Anticancer Res 2003;23:3591-600.
4. Kennedy JC, Pottier RH. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B 1992;6:275-92.
5. Kormeili T, Yamauchi PS, Lowe NJ. Topical photodynamic therapy in clinical dermatology. Br J Dermatol 2004;150:1061-9.
6. Kalka K, Merk H, Mukhtar H. Photodynamic therapy in dermatology. J Am Acad Dermatol 2000;42:389-413.
7. Szeimies RM, Morton CA, Sidoroff A, Braathen LR. Photodynamic therapy for non-melanoma skin cancer. Acta Derm Venereol 2005;85:483-90.
8. Acarturk TO, Edington H. Nonmelanoma skin cancer. Clin Plast Surg 2005;32:237-48.
9. Kelty CJ, Brown NJ, Reed MWR, Ackroyd R. The use of 5-aminolaevulinic acid as a photosensitiser in photodynamic therapy and photodiagnosis. Photochem Photobiol Sci 2002;1:158-68.
10. Ericson MB, Sandberg C, Gudmundson F, et al. Fluorescence contrast and threshold limit: implications for photodynamic diagnosis of basal cell carcinoma. J Photochem Photobiol B 2003;69:121-7.
11. Na R, Stender IM, Wulf HC. Can autofluorescence demarcate basal cell Carcinoma from normal skin? A comparison with protoporphyrin IX fluorescence. Acta Derm Venereol 2001;81:246-9.
12. Kirkup ME, De Berker DA. Clinical measurement of dimensions of basal cell carcinoma: effect of waiting for elective surgery. Br J Dermatol 1999;141:876-9.
13. Gordon PM, Cox NH, Paterson WD, Lawrence CM. Basal cell carcinoma: are early appointments justifiable? Br J Dermatol 2000;142:446-8.